Results 71 to 80 of about 3,260 (145)

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, Volume 209, Issue 3, Page 1010-1019, September 2026.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, Volume 209, Issue 3, Page 874-886, September 2026.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center

Clinical Medicine Insights: Oncology
Zanubrutinib, a next-generation, irreversible, highly potent, and selective Bruton tyrosine kinase inhibitor, is approved by the U.S. Food and Drug Administration to treat patients with B-cell malignancies in 2 dose regimens: 160 mg twice daily (BID) and
Mohit Narang, Courtney Horn, Edward Lee
doaj   +1 more source

Management and long‐term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia‐related neuropathy: A single‐centre experience

British Journal of Haematology, Volume 209, Issue 3, Page 1031-1038, September 2026.
In this 28‐patient retrospective cohort, rituximab‐based regimens for IgM‐related neuropathy yielded significant, sustained functional and neurological improvements over a 2‐year follow‐up. Furthermore, reductions in serum IgM levels correlated with improved Inflammatory Neuropathy Cause and Treatment disability scores, highlighting the long‐term ...
Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Sotirios Manganas, Foteini Theodorakakou, Irene Solia, Evangelos Eleutherakis‐Papaiakovou, Ilias Katsadouros, Panagiotis Boutsikos, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios‐Athanasios Dimopoulos   +15 more
wiley   +1 more source

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Blood Advances
: Some patients with chronic lymphocytic leukemia who develop progressive disease (PD) during covalent Bruton tyrosine kinase (BTK) inhibitor treatment acquire resistance mutations in BTK or PLCG2.
Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman   +12 more
doaj   +1 more source

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders

Pharmacological Research
The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK.
Robert Roskoski, Jr
doaj   +1 more source

Inhibidores de BTK de segunda generación: zanubrutinib Nuevo agente terapéutico para desórdenes linfoproliferativos B

, 2021
Bruton's tyrosine kinase is a tyrosine kinase expressed in the entire hematopoietic lineage, except for T cell progenitors, and plays an essential role in the BCR pathway.
Cugliari, María Silvana
core  

Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia

Revista Portuguesa de Cardiologia
Introduction and objectives: BTK inhibitors (BTKis) have revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL). However, a higher risk of cardiovascular toxicity is reported among CLL patients treated with BTKis. This study aims to
Débora Figueira, João Costa, Manuela Fiuza, Andreia Magalhães, Mariana Paiva, Mariana Saraiva, Pedro Gonçalves-Teixeira, Margarida Borges   +7 more
doaj   +1 more source

IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

, 2022
Context: ASPEN is a randomized, open-label, phase 3 study comparing zanubrutinib, a potent and selective Bruton tyrosine kinase inhibitor (BTKi), with the first-generation BTKi, ibrutinib, in Waldenström macroglobulinemia (WM).
Leblond, V., Marlton, P., Garcia-Sanz, R., Jurczak, W., D'Sa, S., Wahlin, B.E., Cohen, A., Dimopoulos, M., Castillo, J.J., Schneider, J., Buske, C., Siddiqi, T., Owen, R.G., Cull, G., Opat, S., Chan, W.Y., Lee, H.-P., Tedeschi, A., Tam, C.S.   +18 more
core  

Abstracts of 14th International Symposium on Hodgkin Lymphoma

HemaSphere, Volume 10, Issue S2, October 2026.
wiley   +1 more source